drugset / Trial / NCT04482829

TCM in the Treatment of Lung Adenocarcinoma

NCT04482829

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to evaluate the efficacy and safety of Jin-yuan-kang granule in the treatment of lung adenocarcinoma (LUAD) preliminarily, and provide reference for further study.

Timeline

Start
2020-09-15
Primary completion
2020-12-30
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Jing-yan-kang Granule Unknown
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications